Common Contracts
6 similar Securities Purchase Agreement contracts by Armata Pharmaceuticals, Inc., Entasis Therapeutics Holdings Inc.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 11th, 2022 • Armata Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware
This SECURITIES PURCHASE AGREEMENT (together with all Exhibits and Schedules hereto, as each may be amended, restated, amended and restated, supplemented or otherwise modified from time to time in accordance with the terms hereof, this “Agreement”), dated as of February 9, 2022, is made by and between (i) Armata Pharmaceuticals, Inc., a Washington corporation (the “Company”), and (ii) Innoviva Strategic Opportunities LLC, a Delaware limited liability company (the “Purchaser”). The Company and the Purchaser are referred to herein individually as a “Party”, and, collectively as the “Parties.”
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • October 29th, 2021 • Armata Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS SECURITIES PURCHASE AGREEMENT (together with all Exhibits and Schedules hereto, as each may be amended, restated, amended and restated, supplemented or otherwise modified from time to time in accordance with the terms hereof, this “Agreement”), dated as of October 28, 2021, is made by and among (i) Armata Pharmaceuticals, Inc., a Washington corporation (the “Company”), (ii) Cystic Fibrosis Foundation, a Delaware corporation (“CFF”) and (iii) Innoviva Strategic Opportunities LLC, a Delaware limited liability company (“Innoviva” and together with CFF, each a “Purchaser” and collectively, the “Purchasers”). The Company and the Purchasers are referred to herein individually as a “Party”, and, collectively as the “Parties.”
SECURITIES PURCHASE AGREEMENT BY AND BETWEEN ENTASIS THERAPEUTICS HOLDINGS INC. AND INNOVIVA STRATEGIC OPPORTUNITIES LLC Dated as of May 3, 2021Securities Purchase Agreement • May 3rd, 2021 • Entasis Therapeutics Holdings Inc. • Pharmaceutical preparations • Delaware
THIS SECURITIES PURCHASE AGREEMENT (together with all Exhibits and Schedules hereto, as each may be amended, restated, amended and restated, supplemented or otherwise modified from time to time in accordance with the terms hereof, this “Agreement”), dated as of May 3, 2021, is made by and between (i) Entasis Therapeutics Holdings Inc., a Delaware corporation (the “Company”), and (ii) Innoviva Strategic Opportunities LLC (the “Purchaser”). The Company and the Purchaser are referred to herein individually as a “Party,” and, collectively as the “Parties.” Capitalized terms used herein and not otherwise defined herein are defined in Article I hereof.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • January 27th, 2021 • Armata Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS SECURITIES PURCHASE AGREEMENT (together with all Exhibits and Schedules hereto, as each may be amended, restated, amended and restated, supplemented or otherwise modified from time to time in accordance with the terms hereof, this “Agreement”), dated as of January 26, 2021, is made by and between (i) Armata Pharmaceuticals, Inc., a Washington corporation (the “Company”), and (ii) Innoviva Strategic Opportunities LLC, a Delaware limited liability company (the “Purchaser”). The Company and the Purchaser are referred to herein individually as a “Party”, and, collectively as the “Parties.”
SECURITIES PURCHASE AGREEMENT BY AND BETWEEN ENTASIS THERAPEUTICS HOLDINGS INC. AND INNOVIVA, INC. Dated as of April 12, 2020Securities Purchase Agreement • April 13th, 2020 • Entasis Therapeutics Holdings Inc. • Pharmaceutical preparations • Delaware
THIS SECURITIES PURCHASE AGREEMENT (together with all Exhibits and Schedules hereto, as each may be amended, restated, amended and restated, supplemented or otherwise modified from time to time in accordance with the terms hereof, this “Agreement”), dated as of April 12, 2020, is made by and between (i) Entasis Therapeutics Holdings Inc., a Delaware corporation (the “Company”), and (ii) Innoviva, Inc. (the “Purchaser”). The Company and the Purchaser are referred to herein individually as a “Party,” and, collectively as the “Parties.” Capitalized terms used herein and not otherwise defined herein are defined in Article I hereof.
SECURITIES PURCHASE AGREEMENT BY AND BETWEEN Armata Pharmaceuticals, Inc. AND INNOVIVA, INC. Dated as of January 27, 2020 EXHIBITSSecurities Purchase Agreement • January 29th, 2020 • Armata Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS SECURITIES PURCHASE AGREEMENT (together with all Exhibits and Schedules hereto, as each may be amended, restated, amended and restated, supplemented or otherwise modified from time to time in accordance with the terms hereof, this “Agreement”), dated as of January 27, 2020, is made by and between (i) Armata Pharmaceuticals, Inc., a Washington corporation (the “Company”), and (ii) Innoviva, Inc., (the “Purchaser”). The Company and the Purchaser are referred to herein individually as a “Party”, and, collectively as the “Parties.”
